Trial · NCT00734773
Pilot Study of MGd + High-dose MTX-Based Chemoimmunotherapy + RT for Newly Dx PCNSL
NCT00734773, Early phase 1, Withdrawn, Northwestern University
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Pilot Study of MGd + High-dose MTX-Based Chemoimmunotherapy + RT for Newly Dx PCNSL. Trials, record NCT00734773. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00734773
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pilot Study of MGd + High-dose MTX-Based Chemoimmunotherapy + RT for Newly Dx PCNSL
- NCT number
- NCT00734773
- Status
- Withdrawn
- Phases
- Early phase 1
- Enrollment
- 0 participants, actual
- Lead sponsor
- Northwestern University
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Neurotoxicity
- Interventions
- Rituximab, Cytarabine, Methotrexate, Motexafin gadolinium, Procarbazine hydrochloride, Vincristine sulfate, Radiation therapy
- First posted
- 2008-08-14
- Last updated
- 2012-05-18
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Toxicity of motexafin gadolinium (MGd) and rituximab added to high-dose methotrexate, procarbazine hydrochloride, and vincristine (MPV) chemotherapy | Day 1 (every 2 weeks), After 5th cycle, After 7th cycle, Pre Radiation Theray, Post Radiation Therapy, and Post ara-c. | To evaluate toxicity of motexafin gadolinium (MGd) and rituximab to high-dose methotrexate, procarbazine hydrochloride, and vincristine (MPV) chemotherapy at Day 1 (every 2 weeks), After 5th cycle, After 7th cycle, Pre Radiation Theray, Post Radiation Therapy, and Post ara-c. |
| Primary | Toxicity of MGd added to whole-brain radiotherapy (WBRT) | Day 1 (every 2 weeks), After 5th cycle, After 7th cycle, Pre Radiation Theray, Post Radiation Therapy, and Post ara-c. | To evaluate the toxicity of MGd added to whole-brain radiotherapy (WBRT). |
| Primary | Tumor-selective uptake of MGd | Day 1 (every 2 weeks), After 5th cycle, After 7th cycle, Pre Radiation Theray, Post Radiation Therapy, and Post ara-c. | To evaluate Tumor-selective uptake of MGd |
| Secondary | Overall response rate (complete remission [CR] and partial remission [CR]) to pre-radiation chemo-immunotherapy (R-MPV with MGd) | Every 3 months for the first year after completed treatment, every 4 months for the second year, every 6 months until the 5th year and then annually. | MRI scan will be done with each neurologic evaluation. Neuropsychologic evaluation will be repeated approximately 6 months after the completion of therapy and at 6 months intervals thereafter for total of 2 years. |
| Secondary | Complete response rate to pre-radiation chemo-immunotherapy (R-MPV with MGd) | Every 3 months after completion of treatment, exams every 3 months for the first year then every 4 - 6 months thereafter. | Repeat CSF or ocular exam will be done 3 months after completion of treatment in those patients who had evidence of CSF or ocular involvement at diagnosis. CSF will be sampled at each visit. Ocular exams will occur every 3 months for the 1st year then every 4-6 months. Further exams will only be done as needed to rule out recurrent lymphoma. |
| Secondary | Overall survival at 1 year | Every 3 months for the first year after completed treatment, every 4 months for the second year, every 6 months until the 5th year and then annually. | To assess overall survival rate. |
| Secondary | Event-free survival at 1 year | Every 3 months for the first year after completed treatment, every 4 months for the second year, every 6 months until the 5th year and then annually. | To assess event-free survival rate. |
| Secondary | Progression-free survival at 1 year | Every 3 months for the first year after completed treatment, every 4 months for the second year, every 6 months until the 5th year and then annually. | To assess progression-free survival rate. |
| Secondary | Neurotoxicity of R-MVP + MGd based on pre- and post-treatment neuropsychologic testing | At baseline | MR perfusion and MR spectroscopy at baseline and serially when MRI imaging is done to assess response rates using these alternate forms of imaging. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00734773
GET https://conductscience.org/api/trials/v1/NCT00734773/registered